Examining blood cell counts and immune response in triple negative breast cancer
PERCEPTION Trial Protocol: Comparison of Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumour-infiltrating Lymphocytes in Triple Negative Breast Cancer
This study is trying to see how blood cell counts and certain markers can help understand treatment responses and outcomes for people with triple negative breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Jean Perrin Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Clermont-Ferrand, Please Select) |
| Trial ID | NCT04068623 on ClinicalTrials.gov |
What this trial studies
The PERCEPTION study investigates the relationship between various blood cell counts, including neutrophils and lymphocytes, and tumor infiltrating lymphocytes (TILs) in patients with triple negative breast cancer. It aims to analyze these correlations both at baseline and post-surgery, as well as evaluate circulating tumor DNA as a potential predictor of metastatic recurrence. This observational study focuses on understanding how these blood markers can inform treatment responses and outcomes in this aggressive cancer type.
Who should consider this trial
Good fit: Ideal candidates are females over 18 years old diagnosed with non-metastatic, histologically confirmed triple negative breast cancer who have undergone chemotherapy, surgery, and radiation therapy.
Not a fit: Patients who are male or do not have available tumor samples or blood test results at baseline may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into predictive markers for treatment response and recurrence in triple negative breast cancer patients.
How similar studies have performed: While the correlation of these specific markers in triple negative breast cancer has not been thoroughly studied, similar approaches in other cancer types have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female * Age \> 18 years * Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer * Patient treated with chemotherapy, surgery and radiation therapy * Patient able to understand the French language * Patient affiliated to social security * Obtaining signed written consent Exclusion Criteria: * Male * Unavailable tumoral samples before inclusion * Unavailable blood test results at baseline, before inclusion
Where this trial is running
Clermont-Ferrand, Please Select
- Centre Jean PERRIN — Clermont-Ferrand, Please Select, France (Recruiting)
Study contacts
- Principal investigator: Xavier DURANDO, Pr — Centre Jean Perrin
- Study coordinator: Alexia GIRO
- Email: alexia.giro@clermont.unicancer.fr
- Phone: 0033473278005
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.